Last reviewed · How we verify
NCT06601621
Study on the Impact of Electroacupuncture Combined With Self-Acupressure on the Quality of Life of Patients With Early-Stage Breast Cancer Undergoing Chemotherapy
NA trial testing electroacupuncture+ self-acupressure in Electroacupuncture in 192 participants. Currently enrolling.
31 March 2026
Quick facts
| Lead sponsor | Jiuda Zhao |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 192 |
| Start date | 19 October 2024 |
| Primary completion | 31 March 2026 |
| Estimated completion | 30 April 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- electroacupuncture+ self-acupressure
- sham electroacupuncture + sham self-acupressure
Conditions studied
- Electroacupuncture — all drugs for Electroacupuncture →
- Quality of Life (QOL) — all drugs for Quality of Life (QOL) →
- Acupressure — all drugs for Acupressure →
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Jiuda Zhao — full company profile →
Who can join
Adults 18 to 75, any sex, with Electroacupuncture or Quality of Life (QOL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized controlled clinical trial aims to evaluate the effect of electroacupuncture combined with self-acupressure on the quality of life of early-stage breast cancer patients receiving chemotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06601621
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Electroacupuncture
Currently open trials in the same condition.
- NCT07239661 — Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC · NA · recruiting
- NCT06952920 — Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer · Phase 3 · recruiting
- NCT07086300 — Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC · NA · recruiting
- NCT06890260 — The Treatment of Moderate to Severe Allergic Rhinitis With Electroacupuncture Combined With Microneedle Knife · NA · recruiting
- NCT07034326 — Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-smal · Phase 2, PHASE3 · recruiting
Other Jiuda Zhao trials
Trials by the same sponsor.
- NCT06952920 — Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer · Phase 3 · recruiting
- NCT06642441 — Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer · NA · recruiting
- NCT06642428 — Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast C · NA · recruiting
- NCT06200168 — Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer · Phase 3 · recruiting
- NCT05216237 — A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06601621 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiuda Zhao
- Last refreshed: 12 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06601621.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing